Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole

被引：8

作者：

Yamagishi, Hatsushi ^{[1
]}

Koike, Tomoyuki ^{[1
]}

Ohara, Shuichi ^{[1
]}

Horii, Toru ^{[1
]}

Kikuchi, Ryousuke ^{[1
]}

Kobayashi, Shigeyuki ^{[1
]}

Abe, Yasuhiko ^{[1
]}

Iijima, Katsunori ^{[1
]}

Imatani, Akira ^{[1
]}

Suzuki, Kaori ^{[2
]}

Hishinuma, Takanori ^{[3
,4
]}

Goto, Junichi ^{[2
]}

Shimosegawa, Tooru ^{[1
]}

机构：

[1] Tohoku Univ, Div Gastroenterol, Grad Sch Med, Sendai, Miyagi 9808574, Japan

[2] Tohoku Univ, Div Clin Pharm, Sch Pharmaceut Sci, Sendai, Miyagi 9808574, Japan

[3] Tohoku Univ, Div Pharmacotherapy, Sch Pharmaceut Sci, Sendai, Miyagi 9808574, Japan

[4] Tohoku Univ Hosp, Dept Pharmaceut Sci, Sendai, Miyagi 9808574, Japan

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2008年 / 14卷 / 15期

关键词：

lafutidine; lansoprazole; H-2 receptor antagonists; proton pump inhibitors; antisecretory activity;

D O I：

10.3748/wjg.14.2406

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AIM: To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafuticline, a novel H-2 receptor antagonist, with those of the proton pump inhibitor lansoprazole (LPZ) 30 mg. METHODS: Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug. RESULTS: The median intragastric pH was significantly higher in individuals who received lafuticline 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg. CONCLUSION: In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidine than by LPZ. (c) 2008 WJG. All rights reserved.

引用

页码：2406 / 2410

页数：5

共 31 条

[1] COMPARISON OF OMEPRAZOLE AND CIMETIDINE IN REFLUX ESOPHAGITIS - SYMPTOMATIC, ENDOSCOPIC, AND HISTOLOGICAL EVALUATIONS [J].

BATE, CM ;

KEELING, PWN ;

OMORAIN, C ;

WILKINSON, SP ;

FOSTER, DN ;

MOUNTFORD, RA ;

TEMPERLEY, JM ;

HARVEY, RF ;

THOMPSON, DG ;

DAVIS, M ;

FORGACS, IC ;

BASSETT, KS ;

RICHARDSON, PDI .

GUT, 1990, 31 (09) :968-972

[2] Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment [J].

Bour, B ;

Staub, JL ;

Chousterman, M ;

Labayle, D ;

Nalet, B ;

Nouel, O ;

Pariente, A ;

Tocque, E ;

Bonnot-Marlier, S .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (07) :805-812

[3] INTERPHENOTYPE DIFFERENCES IN DISPOSITION AND EFFECT ON GASTRIN-LEVELS OF OMEPRAZOLE - SUITABILITY OF OMEPRAZOLE AS A PROBE FOR CYP2C19 [J].

CHANG, M ;

TYBRING, G ;

DAHL, ML ;

GOTHARSON, E ;

SAGAR, M ;

SEENSALU, R ;

BERTILSSON, L .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (05) :511-518

[4]

DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594

[5]

Farley A, 2000, AM J GASTROENTEROL, V95, P1894

[6]

FELDMAN M, 1993, AM J GASTROENTEROL, V88, P1212

[7] Effects of aging and gastritis on gastric acid and pepsin secretion in humans: A prospective study [J].

Feldman, M ;

Cryer, B ;

McArthur, KE ;

Huet, BA ;

Lee, E .

GASTROENTEROLOGY, 1996, 110 (04) :1043-1052

[8]

Fujimoto K, 2003, J GASTROENTEROL, V38, P3

[9] Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists [J].

Fujisawa, T ;

Adachi, K ;

Komazawa, Y ;

Mihara, T ;

Azumi, T ;

Katsube, T ;

Furuta, K ;

Kazumori, H ;

Kinoshita, Y .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (05) :559-565

[10] Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status [J].

Furuta, T ;

Shirai, N ;

Sugimoto, M ;

Nakamura, A ;

Okudaira, K ;

Kajimura, M ;

Hishida, A .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (01) :67-74

← 1 2 3 4 →